,
,
, L'importance des recherches de mutation de résistance, p.61
,
,
, Références bibliographiques
Point épidémiologique du 23 mars 2017. / Actualités / Infection à VIH et sida / VIH-sida / IST / Maladies infectieuses / Dossiers thématiques, 2017. ,
Impact of late diagnosis and treatment on life expectancy in people with HIV-1: UK Collaborative HIV Cohort (UK CHIC) Study, BMJ, vol.343, p.6016, 2011. ,
State of the Art of Dual Therapy in 2015, AIDS Rev, vol.17, pp.127-161, 2015. ,
Switch to Dolutegravir plus Rilpivirine Dual Therapy in cART-Experienced Subjects: An Observational Cohort, PloS One, vol.11, 2016. ,
Efficacy and safety of dolutegravir and rilpivirine dual therapy as a simplification strategy: a cohort study, HIV Med, vol.18, pp.704-712, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-01906302
Études SWORD 1 et 2 de phase III : le switch vers une stratégie 2DR de DTG/RPV maintient la suppression virologique pendant 48 semaines, Médecine Mal Infect, vol.47, p.142, 2017. ,
Dolutegravir-based monotherapy or dual therapy maintains a high proportion of viral suppression even in highly experienced HIV-1-infected patients, J Antimicrob Chemother, vol.71, 2016. ,
Dolutegravir-lamivudine as initial therapy in HIV-1 infected, ARV-naive patients, 48-week results of the PADDLE (Pilot Antiretroviral Design with Dolutegravir LamivudinE) study, J Int AIDS Soc, vol.20, pp.1-7, 2017. ,
Rilpivirine use in the Swiss HIV cohort study: a prospective cohort study, BMC Infect Dis, vol.17, 2017. ,
, , 2017.
Point épidémiologique du 23 mars 2017. / Actualités / Infection à VIH et sida / VIH-sida / IST / Maladies infectieuses / Dossiers thématiques, 2017. ,
A new human immunodeficiency virus derived from gorillas, Nat Med, vol.15, pp.871-873, 2009. ,
Long-term nonprogressors and elite controllers in the ANRS CO5 HIV-2 cohort, AIDS Lond Engl, vol.25, pp.865-872, 2011. ,
Comparison of viro-immunological marker changes between HIV-1 and HIV-2-infected patients in France, AIDS Lond Engl, vol.22, pp.457-68, 2008. ,
URL : https://hal.archives-ouvertes.fr/inserm-00258131
The therapeutic application of CRISPR/Cas9 technologies for HIV, Expert Opin Biol Ther, vol.15, pp.819-849, 2015. ,
HIV-1 Reservoirs During Suppressive Therapy, Trends Microbiol, vol.24, pp.345-55, 2016. ,
HIV reservoirs as obstacles and opportunities for an HIV cure, Nat Immunol, vol.16, pp.584-593, 2015. ,
Human adipose tissue as a reservoir for memory CD4+ T cells and HIV, AIDS Lond Engl, vol.29, pp.667-74, 2015. ,
Peripheral T Follicular Helper Cells Are the Major HIV Reservoir within Central Memory CD4 T Cells in Peripheral Blood from Chronically HIV-Infected Individuals on Combination Antiretroviral Therapy, J Virol, vol.90, pp.2718-2746, 2015. ,
NRTI backbone in HIV treatment: will it remain relevant?, Drugs, vol.72, pp.2051-62, 2012. ,
Clinical pharmacology of tenofovir clearance: a pharmacokinetic/pharmacogenetic study on plasma and urines, Pharmacogenomics J, vol.16, pp.514-522, 2016. ,
, Ann Pharmacother, vol.50, pp.942-52, 2016.
HIV-1 NNRTIs: structural diversity, pharmacophore similarity, and implications for drug design, Med Res Rev, vol.33, issue.1, pp.1-72, 2013. ,
Induction of PGlycoprotein and Cytochrome P450 3A by HIV Protease Inhibitors, Drug Metab Dispos, vol.29, pp.754-60, 2001. ,
Protease Inhibitors as Inhibitors of Human Cytochromes P450: High Risk Associated with Ritonavir, J Clin Pharmacol, vol.38, pp.106-117, 1998. ,
Pathogenesis of HIV-1-protease inhibitorassociated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance, The Lancet, vol.351, pp.3391-3392, 1998. ,
Susceptibility to protease inhibitors in HIV-2 primary isolates from patients failing antiretroviral therapy, J Antimicrob Chemother, vol.57, pp.709-722, 2006. ,
In Vitro Phenotypic Susceptibility of Human Immunodeficiency Virus Type 2 Clinical Isolates to Protease Inhibitors, Antimicrob Agents Chemother, vol.52, pp.1545-1553, 2008. ,
URL : https://hal.archives-ouvertes.fr/inserm-00263591
Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: A platform for antiviral drug design, Proc Natl Acad Sci, vol.96, pp.13040-13043, 1999. ,
Pharmacology of HIV integrase inhibitors, Curr Opin HIV AIDS, vol.7, pp.390-400, 2012. ,
, Drugs, vol.63, pp.2767-2768, 2003.
Enfuvirtide: from basic investigations to current clinical use, Expert Opin Pharmacother, vol.11, pp.2701-2714, 2010. ,
Structure of the CCR5 chemokine receptor-HIV entry inhibitor maraviroc complex, Science, vol.341, pp.1387-90, 2013. ,
Maraviroc: a review of its use in HIV infection and beyond, Drug Des Devel Ther, vol.9, pp.5447-68, 2015. ,
, Weekends-off efavirenz-based antiretroviral therapy in HIV-infected children, adolescents, and young adults (BREATHER): a randomised, open-label, non-inferiority, phase 2/3 trial, BREATHER (PENTA 16) Trial Group, vol.3, pp.30054-30060, 2016.
Efficacy of a maintenance four-days-a-week regimen: the ANRS1624D trial, 21st International AIDS Conference ,
Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study, Lancet Infect Dis, vol.15, pp.793-802, 2015. ,
Reduced darunavir dose is as effective in maintaining HIV suppression as the standard dose in virologically suppressed HIV-infected patients: a randomized clinical trial, J Antimicrob Chemother, vol.70, pp.1139-1184, 2015. ,
, Maintenance Therapy With 400/100 mg of Darunavir/Ritonavir for 48 Weeks n, 2017.
Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV, AIDS Lond Engl, vol.22, pp.1-9, 2008. ,
Randomized controlled study demonstrating failure of LPV/r monotherapy in HIV: the role of compartment and CD4-nadir, AIDS Lond Engl, vol.24, pp.2347-54, 2010. ,
Efficacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136, AIDS Lond Engl, vol.24, pp.2365-74, 2010. ,
Cellular HIV reservoir replenishment is not affected by blip or intermittent viremia episodes during darunavir/ritonavir monotherapy, AIDS Lond Engl, vol.28, pp.201-209, 2014. ,
The PROTEA trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV-1 RNA below 50 copies/mL, J Int AIDS Soc, vol.17, 2014. ,
Effectiveness of protease inhibitor monotherapy versus combination antiretroviral maintenance therapy: a meta-analysis, PloS One, vol.6, 2011. ,
Dolutegravir monotherapy in HIV-infected patients with sustained viral suppression, J Antimicrob Chemother, vol.71, pp.1975-81, 2016. ,
Dolutegravir as monotherapy in HIV-1-infected individuals with suppressed HIV viraemia, J Antimicrob Chemother, vol.71, pp.2646-50, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01340219
, , 2017.
Dolutegravir-based monotherapy or dual therapy maintains a high proportion of viral suppression even in highly experienced HIV-1-infected patients, J Antimicrob Chemother, vol.71, 2016. ,
Efficacy and safety of contemporary dualdrug antiretroviral regimens as first-line treatment or as a simplification strategy: a systematic review and meta-analysis, Lancet HIV, vol.3, issue.16, pp.30015-30022, 2016. ,
Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study, J Antimicrob Chemother, vol.64, pp.118-143, 2009. ,
Outcomes of patients on dual-boosted PI regimens: experience of the Swiss HIV cohort study, AIDS Res Hum Retroviruses, vol.26, pp.1239-1285, 2010. ,
LongTerm HIV-1 Virologic Control in Patients on a Dual NRTI Regimen, HIV Clin Trials, vol.14, pp.120-126, 2013. ,
Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviraltherapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial, Lancet Infect Dis, vol.14, pp.572-80, 2014. ,
, ANRS 167 LAMIDOL TRIAL | CROI Conference, 2017.
Ritonavirboosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial, Lancet Lond Engl, vol.384, issue.14, pp.61170-61173, 2014. ,
URL : https://hal.archives-ouvertes.fr/hal-01108186
Dolutegravir: clinical and laboratory safety in integrase inhibitor-naive patients, HIV Clin Trials, vol.15, pp.199-208, 2014. ,
48-week efficacy and safety of dolutegravir relative to commonly used third agents in treatment-naive HIV-1-infected patients: a systematic review and network meta-analysis, PloS One, vol.9, p.105653, 2014. ,
Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection, N Engl J Med, vol.369, pp.1807-1825, 2013. ,
Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study, Lancet Lond Engl, vol.383, issue.14, pp.60084-60086, 2014. ,
Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study, Lancet Lond Engl, vol.381, pp.735-778, 2013. ,
Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study, J Infect Dis, vol.207, pp.740-748, 2013. ,
A phase 1 study to evaluate the effect of dolutegravir on renal function via measurement of iohexol and para-aminohippurate clearance in healthy subjects, Br J Clin Pharmacol, vol.75, pp.990-996, 2013. ,
Tolerability of integrase inhibitors in a real-life setting, J Antimicrob Chemother, vol.72, pp.1752-1761, 2017. ,
Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients, HIV Med, vol.18, pp.56-63, 2017. ,
Traitement de l'infection VIH par inhibiteurs d'intégrase : plus d'options, Virologie, vol.17, issue.2, 2013. ,
The effect of dolutegravir on the pharmacokinetics of metformin in healthy subjects, J Int AIDS Soc, vol.17, 2014. ,
Pharmacokinetics of Dolutegravir When Administered With Mineral Supplements in Healthy Adult Subjects, J Clin Pharmacol, vol.55, pp.490-496, 2015. ,
Safety, tolerability and pharmacokinetics of rilpivirine following administration of a long-acting formulation in healthy volunteers, HIV Med, vol.16, pp.477-84, 2015. ,
Long-term efficacy, safety, and tolerability of rilpivirine (RPV, TMC278) in HIV type 1infected antiretroviral-naive patients: week 192 results from a phase IIb randomized trial, AIDS Res Hum Retroviruses, vol.28, pp.437-483, 2012. ,
Effectiveness and safety of rilpivirine, a nonnucleoside reverse transcriptase inhibitor, in treatment-naive adults infected with HIV1: a meta-analysis, HIV Clin Trials, vol.15, pp.261-269, 2014. ,
Renal tubular transporter-mediated interactions of HIV drugs: implications for patient management, AIDS Rev, vol.16, pp.199-212, 2014. ,
Clinical perspective on drug-drug interactions with the non-nucleoside reverse transcriptase inhibitor rilpivirine, AIDS Rev, vol.15, pp.87-101, 2013. ,
Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients, Clin Infect Dis Off Publ Infect Dis Soc Am, vol.51, pp.496-505, 2010. ,
Renal function in patients with HIV starting therapy with tenofovir and either efavirenz, lopinavir or atazanavir, AIDS Lond Engl, vol.26, pp.567-75, 2012. ,
DOI : 10.1097/qad.0b013e32834f337c
Role of Traditional Risk Factors and Antiretroviral Drugs in the Incidence of Chronic Kidney Disease, PLoS ONE, vol.8, 2004. ,
URL : https://hal.archives-ouvertes.fr/hal-01101114
Efficacy and safety 48 weeks after switching from efavirenz to rilpivirine using emtricitabine/tenofovir disoproxil fumarate-based single-tablet regimens, HIV Clin Trials, vol.14, pp.216-239, 2013. ,
DOI : 10.1310/hct1405-216
Low bone mineral density, renal dysfunction, and fracture risk in HIV infection: a cross-sectional study, J Infect Dis, vol.200, pp.1746-54, 2009. ,
Bone turnover, osteoprotegerin/RANKL and inflammation with antiretroviral initiation: tenofovir versus non-tenofovir regimens, Antivir Ther, vol.16, 2011. ,
Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy, AIDS Lond Engl, vol.14, pp.63-67, 2000. ,
Reduced bone mineral density in HIV-positive individuals, AIDS Lond Engl, vol.15, pp.1731-1734, 2001. ,
DOI : 10.1097/00002030-200109070-00019
Clinical syndromes and consequences of antiretroviral-related hepatotoxicity, Hepatol Baltim Md, vol.52, pp.1143-55, 2010. ,
Causes of death among HIV-infected patients in France in 2010 (national survey): trends since, AIDS Lond Engl, vol.28, pp.1181-91, 2000. ,
Simplification to rilpivirine/emtricitabine/tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1 RNA-suppressed participants, AIDS Lond Engl, vol.28, pp.335-379, 2014. ,
Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study, AIDS Lond Engl, vol.24, pp.1697-707, 2010. ,
Randomised Study to Assess the Efficacy and Safety of Once-Daily Etravirine-Based Regimen as a Switching Strategy in HIV-Infected Patients Receiving a Protease Inhibitor-Containing Regimen, Etraswitch Study. PLoS ONE, vol.9, 2014. ,
Rilpivirine exposure in plasma and sanctuary site compartments after switching from nevirapinecontaining combined antiretroviral therapy, J Antimicrob Chemother, vol.69, pp.1642-1649, 2014. ,
ING116070: a study of the pharmacokinetics and antiviral activity of dolutegravir in cerebrospinal fluid in HIV-1-infected, antiretroviral therapy-naive subjects, Clin Infect Dis Off Publ Infect Dis Soc Am, vol.59, pp.1032-1039, 2014. ,
Prevalence of HIV-1 drug resistance in treated patients with viral load >50 copies/mL: a 2014 French nationwide study, J Antimicrob Chemother, vol.72, pp.1769-73, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-01984209